- Home
- IMAB vs GNTA Comparison
IMAB vs GNTA Comparison
Compare IMAB & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- GNTA
- Stock Information
- Founded
- IMAB 2014
- GNTA 2014
- Country
- IMAB United States
- GNTA Italy
- Employees
- IMAB N/A
- GNTA N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMAB Health Care
- GNTA Health Care
- Exchange
- IMAB Nasdaq
- GNTA Nasdaq
- Market Cap
- IMAB 83.8M
- GNTA 67.4M
- IPO Year
- IMAB 2020
- GNTA 2021
- Fundamental
- Price
- IMAB $1.39
- GNTA $4.40
- Analyst Decision
- IMAB Strong Buy
- GNTA Strong Buy
- Analyst Count
- IMAB 3
- GNTA 1
- Target Price
- IMAB $8.00
- GNTA $25.00
- AVG Volume (30 Days)
- IMAB 378.4K
- GNTA 8.3K
- Earning Date
- IMAB 08-28-2024
- GNTA 01-01-0001
- Dividend Yield
- IMAB N/A
- GNTA N/A
- EPS Growth
- IMAB N/A
- GNTA N/A
- EPS
- IMAB N/A
- GNTA N/A
- Revenue
- IMAB $3,492,091.00
- GNTA N/A
- Revenue This Year
- IMAB N/A
- GNTA N/A
- Revenue Next Year
- IMAB N/A
- GNTA N/A
- P/E Ratio
- IMAB N/A
- GNTA N/A
- Revenue Growth
- IMAB N/A
- GNTA N/A
- 52 Week Low
- IMAB $0.99
- GNTA $2.20
- 52 Week High
- IMAB $2.54
- GNTA $5.87
- Technical
- Relative Strength Index (RSI)
- IMAB 63.28
- GNTA 57.18
- Support Level
- IMAB $1.02
- GNTA $3.86
- Resistance Level
- IMAB $1.50
- GNTA $4.50
- Average True Range (ATR)
- IMAB 0.10
- GNTA 0.29
- MACD
- IMAB 0.04
- GNTA 0.08
- Stochastic Oscillator
- IMAB 77.08
- GNTA 91.67
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.